1. Weight‐loss response to naltrexone/bupropion is modulated by the <scp>Taq1A</scp> genetic variant near <scp> DRD2 </scp> ( <scp>rs1800497</scp> ): A pilot study
- Author
-
Jamie A. Mullally, Rajasekhar Ramakrishnan, Steven Holleran, Tirissa J. Reid, Charles A. LeDuc, Gerardo Febres, Wendy K. Chung, and Judith Korner
- Subjects
Bupropion ,Dopamine binding ,ANKK1 ,medicine.medical_specialty ,business.industry ,Endocrinology, Diabetes and Metabolism ,media_common.quotation_subject ,Appetite ,Naltrexone ,Endocrinology ,Weight loss ,Internal medicine ,Genotype ,Internal Medicine ,medicine ,medicine.symptom ,business ,Pharmacogenetics ,medicine.drug ,media_common - Abstract
Naltrexone/bupropion (NB) is a US Food and Drug Administration-approved antiobesity medication. Clinical trials have shown variable weight loss, with responders and non-responders. NB is believed to act on central dopaminergic pathways to suppress appetite. The Taq1A polymorphism near DRD2 (rs1800497) is associated with the density of striatal dopamine D2 receptors, with individuals carrying the A allele (AA or AG; termed A1+) having 30%-40% fewer dopamine binding sites than those who do not carry the A allele (GG; termed A1-). We performed a pilot study to assess the association of the rs1800497 ANKK1 c.2137G > A (p.Glu713Lys) variant with weight loss with NB treatment in 33 subjects. Mean (SD) weight loss was 5.9% (3.2%) for the A1+ genotype group (n = 15) and 4.2% (4.2%) for the A1- genotype group (n = 18). The mean weight loss for the A1+ genotype group was significantly greater than the predefined clinically significant 4% weight-loss target (one-sample t-test, P = .035), whereas the mean weight loss for the A1- genotype group was not (P = .85). Individuals with the A1+ genotype appear to respond better to NB than A1- individuals.
- Published
- 2021
- Full Text
- View/download PDF